Comparison of Tomographic Findings in Patients with Influenza A (H1N1) and COVID-19.

Publication date: Jun 04, 2025

Objectives: The objective of this study was to identify CT-based predictors of mechanical ventilation and mortality in patients with severe and critical viral pneumonia and to examine the association between imaging severity and outcomes in ventilated patients. Methods: We analyzed pulmonary CT scans from 148 patients with severe or critical pneumonia caused by COVID-19 (n = 98) or influenza A H1N1 (n = 50). Patients were assessed based on tomographic patterns, demographics, clinical severity scores (Charlson Comorbidity Index, SOFA, and APACHE IV), and biomarkers. Survival analyses were performed using Kaplan-Meier curves and multivariable Cox regression. Results: Bilateral, peripheral, and basal lung involvement was common across both groups. Ground-glass opacities (89. 62%, p ≤ 0. 001) and consolidation (61. 54%, p = 0. 001) were more prevalent in COVID-19, whereas pleural effusion was significantly more frequent in H1N1 (76. 92%, p ≤ 0. 001). COVID-19 cases more often presented with bilateral (96. 94%) and peripheral lesions (77. 87%). H1N1 patients were more likely to develop severe ARDS and require mechanical ventilation. In COVID-19, higher APACHE IV scores and pulmonary damage severity index were independently associated with increased mortality. Conclusions: Radiologic and clinical severity profiles differ between COVID-19 and H1N1 pneumonia. CT-based assessments combined with prognostic scores may aid early risk stratification and guide treatment decisions in patients with severe viral pneumonia.

Open Access PDF

Concepts Keywords
Apache artificial respiration
Biomarkers mortality
Pneumonia organ dysfunction scores
Sofa SARS-CoV-2 (COVID-19)
Viral

Semantics

Type Source Name
pathway KEGG Influenza A
disease MESH COVID-19
disease MESH viral pneumonia
disease MESH pneumonia
disease MESH Comorbidity
disease MESH pleural effusion
disease MESH Influenza
drug DRUGBANK Coenzyme M
disease MESH Zona
disease MESH organ dysfunction scores
disease MESH morbidity
disease MESH critically ill
disease MESH infections
disease MESH abnormalities
disease MESH lymphadenopathy
drug DRUGBANK Methyprylon
disease MESH viral infections
disease MESH emergency
drug DRUGBANK Oxygen
disease MESH etiology
disease MESH malignancies
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH cardiac failure
disease MESH respiratory insufficiency
drug DRUGBANK Creatinine
disease MESH shock
disease MESH embolism
drug DRUGBANK Sulodexide
disease MESH bronchiectasis
disease MESH pulmonary embolism
disease MESH thrombus
disease MESH atelectasis
disease IDO infection
drug DRUGBANK Ilex paraguariensis leaf
disease MESH death
disease MESH Acute Respiratory Distress Syndrome
drug DRUGBANK Gold
disease IDO virulence
disease MESH pulmonary injury
disease MESH COPD
disease MESH tic
disease MESH fibrosis
disease MESH coinfections
disease MESH bacterial pneumonia
disease MESH Infectious Diseases
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH sequelae
disease MESH severe acute respiratory syndrome
drug DRUGBANK Guanosine
drug DRUGBANK Influenza A virus

Original Article

(Visited 1 times, 1 visits today)